MyFinsight
Home
Blog
About
ALLURION TECHNOLOGIES, INC. (ALUR)
ALLURION TECHNOLOGIES, INC. (ALUR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$355K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Warrant inducement expense
Proceeds from warrant inducement...
Change in fair value of revenue ...
Others
Negative Cash Flow Breakdown
Change in fair value of warrant ...
General and administrative
Other segment items
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
2,947
15,230
-
-
Cost of revenue
1,718
5,659
-
-
Sales and marketing
1,304
10,804
-
-
Research and development-Clinical Trials And Medical Affairs
343
3,020
-
-
Research and development-Product Development
205
1,848
-
-
Research and development-Digital
98
969
-
-
Research and development-Quality And Regulatory
266
1,733
-
-
General and administrative
2,744
21,353
-
-
Interest paid on debt recorded at fair value
-
379
481
1,550
Provision for uncollectible accounts
-
1,058
946
771
Other segment items
-2,364
1,401
-
-
Loss on extinguishment of debt
-
0
0
-660
Net loss
-6,095
-6,035
-11,884
-9,335
Non-cash lease expense
119
127
113
227
Depreciation and amortization
171
165
268
347
Stock-based compensation
638
702
531
1,016
Other non-cash items, net
-
-
-269
851
Unrealized exchange gain (loss) and other
-
206
-
-
Unrealized exchange (gain) loss
-90
-
-
-
Change in fair value of revenue interest financing and pipe conversion option
-
-2,759
-2,571
60
Provision for inventory
433
717
55
419
Change in fair value of warrant liabilities
-4,324
-3,586
-1,481
-2,064
Change in fair value of earn-out liabilities
-
62
-18
105
Warrant inducement expense
4,145
-
-
-
Change in fair value of debt
750
1,165
1,250
4,530
Change in fair value of revenue interest financing
-1,820
-
-
-
Change in fair value of share obligation
-120
-430
-110
210
Issuance costs associated with warrants recorded at fair value
222
365
0
0
Accounts receivable
-365
1,387
-865
-2,249
Inventory
-176
-278
-53
839
Prepaid expenses, other current and long-term assets
-172
-316
-327
-10
Lease liabilities
-73
-184
-76
-337
Accounts payable
-347
673
-921
-484
Accrued expenses and other current liabilities
-1,363
-1,958
1,143
-2,762
Net cash used in operating activities
-3,221
-5,320
-6,544
-7,613
Proceeds from private offerings, net of issuance costs
-
4,597
-
-
Proceeds from public offerings, net of issuance costs
-
0
-87
13,665
Proceeds from equity line financing
-
0
32
763
Proceeds from warrant inducement, net of issuance costs
2,866
-
-
-
Net cash provided by financing activities
2,866
4,597
-55
-71
Net increase (decrease) in cash and cash equivalents and restricted cash
-355
-723
-6,599
-7,684
Cash and cash equivalents and restricted cash at beginning of period
5,742
6,465
15,718
-
Cash and cash equivalents and restricted cash at end of period
5,387
5,742
6,465
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from warrant
inducement, net of issuance...
$2,866K
Net cash provided by
financing activities
$2,866K
(-80.23%↓ Y/Y)
Net increase
(decrease) in cash and cash...
-$355K
(-107.06%↓ Y/Y)
Canceled cashflow
$2,866K
Warrant inducement
expense
$4,145K
Change in fair value of
revenue interest...
-$1,820K
Change in fair value of
debt
$750K
(122.52%↑ Y/Y)
Stock-based compensation
$638K
(-28.87%↓ Y/Y)
Provision for inventory
$433K
(1632.00%↑ Y/Y)
Accounts receivable
-$365K
(-141.34%↓ Y/Y)
Issuance costs
associated with warrants...
$222K
(-80.47%↓ Y/Y)
Inventory
-$176K
(-700.00%↓ Y/Y)
Prepaid expenses, other
current and long-term...
-$172K
(-17.01%↓ Y/Y)
Depreciation and
amortization
$171K
(-15.76%↓ Y/Y)
Non-cash lease expense
$119K
(-43.87%↓ Y/Y)
Unrealized exchange (gain)
loss
-$90K
(-126.87%↓ Y/Y)
Net cash used in
operating activities
-$3,221K
(65.98%↑ Y/Y)
Canceled cashflow
$9,101K
Revenue
$2,947K
Net loss
-$6,095K
(-306.06%↓ Y/Y)
Canceled cashflow
$2,947K
Change in fair value of
warrant liabilities
-$4,324K
(23.73%↑ Y/Y)
Accrued expenses and
other current...
-$1,363K
(7.15%↑ Y/Y)
Accounts payable
-$347K
(85.60%↑ Y/Y)
Change in fair value of
share obligation
-$120K
(-117.14%↓ Y/Y)
Lease liabilities
-$73K
(63.32%↑ Y/Y)
General and
administrative
$2,744K
Other segment items
-$2,364K
Cost of revenue
$1,718K
Sales and marketing
$1,304K
Research and
development-Clinical Trials And...
$343K
Research and
development-Quality And Regulatory
$266K
Research and
development-Product Development
$205K
Research and
development-Digital
$98K
Buy us a coffee